Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

57806 Results Found

Congress urged to preserve tax-exempt status of municipal bonds

The AHA yesterday commended Senate Finance Committee Chairman Orrin Hatch (R-UT) for maintaining tax exemption for private activity bonds in his 

AHA, others urge Congress to protect tax-exempt private activity bonds

A coalition of 35 national organizations, including the AHA, today urged House and Senate leaders to “protect in full” the current federal income tax treatment of private activity bonds, as envisio

CHI, Dignity Health to combine to form new health system

Catholic Health Initiatives and Dignity Health today

FDA issues guidance on its digital health regulatory policies

The Food and Drug Administration today released for comment draft

AHA recommends FDA actions to ease regulation, improve device security

AHA again urged the Food and Drug Administration today to allow health system pharmacies to distribute compounded products to other system facilities located more than one mile away.

Health system shares lessons from MACRA journey in AHA-ASA podcast series

In a new AHA podcast series produced with the American Society of Anesthesiologists, hospital and clinici

AHA urges MedPAC to withdraw 340B payment proposal

The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program.

AHA critical of MedPAC's "misdirected" 340B payment proposal

The AHA last week criticized as “misdirected” and a blow to patient care the Medicare Payment Assessment Commission’s (MedPAC) recommendation that Congress reduce Part B drug payment rates to hospi

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

AHASTAT blog: Reducing 340B is not the answer to curbing skyrocketing drug prices

A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickel